Giannopoulos Georgios, Angelidis Christos, Papoutsidakis Nikolaos, Panagopoulou Vasiliki, Cleman Michael W, Lekakis John, Deftereos Spyridon
Yale University School of Medicine, Int Med - Cardiology, PO BOX 208017, New Haven, CT 06520- 8017, USA.
Curr Med Chem. 2015;22(36):4177-88. doi: 10.2174/0929867322666151015120458.
Colchicine has recently gained considerable attention in the field of cardiovascular research, after a number of studies showed that it may be of use in several settings of cardiovascular disease, including chronic coronary artery disease and following stent implantation. Its unique anti-inflammatory mechanism of action makes it safe to use in patients with cardiovascular disease, unlike most--if not all--currently available antiinflammatory agents. While its prophylactic and therapeutic value is well-established in certain conditions involving an acute inflammatory response, e.g. pericarditis, in other conditions, including coronary artery disease and heart failure, which are associated with a chronic low-grade inflammatory state, the evidence regarding its potential use remains sparse. In this concise review, we present key features of this drug and the rationale for colchicine therapy, in the context of acute and chronic coronary artery disease, as well as in ischemic heart failure and critically examine the evidence concerning a possible future role of colchicine treatment in these conditions.
在多项研究表明秋水仙碱可能对包括慢性冠状动脉疾病和支架植入术后在内的多种心血管疾病有用之后，它最近在心血管研究领域受到了相当大的关注。与目前大多数（如果不是全部）可用的抗炎药物不同，其独特的抗炎作用机制使其在心血管疾病患者中使用是安全的。虽然其预防和治疗价值在某些涉及急性炎症反应的病症（如心包炎）中已得到充分证实，但在其他与慢性低度炎症状态相关的病症（包括冠状动脉疾病和心力衰竭）中，关于其潜在用途的证据仍然很少。在这篇简要综述中，我们阐述了这种药物的关键特性以及秋水仙碱治疗的基本原理，涉及急性和慢性冠状动脉疾病、缺血性心力衰竭，并严格审视了有关秋水仙碱治疗在这些病症中可能的未来作用的证据。
